VRTX - Vertex Pharmaceuticals Incorporated
NASDAQ
->
Healthcare
->
Biotechnology
Boston,
United States
Type: Equity
VRTX price evolution
VRTX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4580.1 | $9158 | $10369.1 | |
| Short term investments | $1215.4 | $1013.3 | $849.2 | |
| Net receivables | $1750.6 | $1656.1 | $1793.2 | $1563.4 |
| Inventory | $1079.8 | $914.6 | $813.1 | $738.8 |
| Total current assets | $9804.1 | $8941.6 | $13288.7 | $14144.2 |
| Long term investments | $4393.1 | $4381.4 | $2497.8 | |
| Property, plant & equipment | $2513.9 | $1770.7 | $1485.7 | $1452.9 |
| Goodwill & intangible assets | $1925.5 | $1922.9 | $1927.9 | |
| Total noncurrent assets | $11190.5 | $10628.7 | $8586 | |
| Total investments | $5608.5 | $5394.7 | $3347 | |
| Total assets | $22240.2 | $20132.1 | $23917.4 | $22730.2 |
| Current liabilities | ||||
| Accounts payable | $3615.5 | $327.9 | $351.4 | $3020.2 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3973.1 | $3547.2 | $3795.9 | $3547.4 |
| Long term debt | $114 | $933.4 | $721.3 | $376.1 |
| Total noncurrent liabilities | $1810.2 | $1574.9 | $1602.4 | |
| Total debt | $933.4 | $721.3 | $724.7 | |
| Total liabilities | $6609.3 | $5357.4 | $5370.8 | $5149.8 |
| Shareholders' equity | ||||
| Retained earnings | $8693.8 | $7648.4 | $11242 | $10142.4 |
| Other shareholder equity | $15630.9 | $22.5 | $17.3 | $17580.4 |
| Total shareholder equity | $14774.7 | $18546.6 | $17580.4 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $10369.1 | $10504 | $6795 | $5988.19 |
| Short term investments | $849.2 | $274.5 | $729.9 | $670.71 |
| Net receivables | $1563.4 | $1442.2 | $1136.8 | $885.35 |
| Inventory | $738.8 | $460.6 | $353.1 | $280.78 |
| Total current assets | $14144.2 | $12681.3 | $9560.6 | $8133.38 |
| Long term investments | $2497.8 | $20.8 | ||
| Property, plant & equipment | $1452.9 | $1108.4 | $1424.4 | $1284.1 |
| Goodwill & intangible assets | $1927.9 | $1691.6 | $1402.2 | $1402.16 |
| Total noncurrent assets | $8586 | $4916.1 | $3871.9 | $3618.43 |
| Total investments | $3347 | $274.5 | $729.9 | $670.71 |
| Total assets | $22730.2 | $18150.9 | $13432.5 | $11751.81 |
| Current liabilities | ||||
| Accounts payable | $3020.2 | $2430.6 | $195 | $155.14 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3547.4 | $2430.6 | $2142 | $1877.53 |
| Long term debt | $376.1 | $471.6 | $887.2 | $889.5 |
| Total noncurrent liabilities | $1602.4 | $1496.1 | $1190.5 | $1187.46 |
| Total debt | $724.7 | $810.3 | $887.2 | $889.5 |
| Total liabilities | $5149.8 | $4238.2 | $3332.5 | $3064.99 |
| Shareholders' equity | ||||
| Retained earnings | $10142.4 | $6522.8 | $3200.8 | $858.67 |
| Other shareholder equity | $17580.4 | $13912.7 | $15.9 | -$68.48 |
| Total shareholder equity | $17580.4 | $13912.7 | $10100 | $8686.82 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2771.9 | $2645.6 | $2690.6 | $2517.7 |
| Cost of revenue | $371.9 | $342.6 | ||
| Gross Profit | $2379.3 | $2273.7 | $2348 | $2149.7 |
| Operating activities | ||||
| Research & development | $966.6 | $789.1 | ||
| Selling, general & administrative | $372.2 | $342.7 | ||
| Total operating expenses | $1248 | $5787.9 | $1208.6 | $1161.2 |
| Operating income | -$3514.2 | $1139.4 | ||
| Income from continuing operations | ||||
| EBIT | -$3381.3 | $1289.5 | ||
| Income tax expense | $178.7 | $202.4 | $179.5 | $178.8 |
| Interest expense | $124.7 | $9.9 | $10.4 | $168.9 |
| Net income | ||||
| Net income | $1045.4 | -$3593.6 | $1099.6 | $968.8 |
| Income (for common shares) | -$3593.6 | $1099.6 | ||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9869.2 | $8930.7 | $6205.68 | |
| Cost of revenue | $1080.3 | $736.3 | ||
| Gross Profit | $8607 | $7850.4 | $5469.38 | |
| Operating activities | ||||
| Research & development | $2540.3 | $1829.54 | ||
| Selling, general & administrative | $944.7 | $770.46 | ||
| Total operating expenses | $4775 | $3600.5 | $2599.99 | |
| Operating income | $4249.9 | $2869.39 | ||
| Income from continuing operations | ||||
| EBIT | $4287.2 | $3174.95 | ||
| Income tax expense | $760.2 | $910.4 | $405.15 | |
| Interest expense | $570.6 | $54.8 | $58.15 | |
| Net income | ||||
| Net income | $3619.6 | $3322 | $2711.65 | |
| Income (for common shares) | $3322 | $2711.65 | ||
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$3593.6 | $1099.6 | $968.8 | |
| Operating activities | ||||
| Depreciation | $54 | $53.5 | $59 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $154.2 | $191.9 | $208.6 | |
| Total cash flows from operations | -$3753.6 | $1306.6 | $234.6 | |
| Investing activities | ||||
| Capital expenditures | -$69 | -$68.4 | -$58.1 | |
| Investments | -$372 | -$1888 | -$770.4 | |
| Total cash flows from investing | -$2948.1 | -$463.7 | -$2136.4 | -$886.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$345.8 | -$347.8 | -$106.3 | |
| Net borrowings | -$13.7 | -$13.2 | -$10.2 | |
| Total cash flows from financing | -$1103.6 | -$358.6 | -$357.5 | -$119.8 |
| Effect of exchange rate | $4.7 | -$2.5 | -$15.6 | $27.4 |
| Change in cash and equivalents | -$5124.2 | -$4578.4 | -$1202.9 | -$744.3 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $3619.6 | $3322 | $2342.1 | $2711.65 |
| Operating activities | ||||
| Depreciation | $181.3 | $148.3 | $125.6 | $109.52 |
| Business acquisitions & disposals | -$295.9 | |||
| Stock-based compensation | $581.2 | $491.3 | $441.4 | $429.46 |
| Total cash flows from operations | $3537.3 | $4129.9 | $2643.5 | $3253.51 |
| Investing activities | ||||
| Capital expenditures | -$200.4 | -$204.7 | -$235 | -$259.8 |
| Investments | -$2883.3 | $179.5 | -$105.9 | $359.19 |
| Total cash flows from investing | -$3141.7 | -$321.1 | -$340.9 | $99.39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$519.1 | $14.3 | -$1459.3 | -$474.46 |
| Net borrowings | -$43.1 | -$85.5 | -$24.4 | -$29.02 |
| Total cash flows from financing | -$562.2 | -$67.7 | -$1478 | -$505.28 |
| Effect of exchange rate | $26.9 | -$29.2 | -$13.4 | $20.55 |
| Change in cash and equivalents | -$139.7 | $3711.9 | $811.2 | $2868.16 |
News
Fundamentals
| Market cap | $105.54B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 257.70M |
| Revenue | $10.63B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$479.80M |
| Revenue Q/Q | 11.61% |
| Revenue Y/Y | 10.06% |
| P/E ratio | -219.97 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 9.93 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.86 |
|---|---|
| ROA | -2.16% |
| ROE | N/A |
| Debt/Equity | 0.29 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.47 |
| Quick ratio | 2.20 |